Featured Content

OBR Daily   Our free daily oncology focused e-news service.
Subscribe»  |  Search Archives»

Today's News

Exelixis Announces European Commission Approval of COTELLIC™ (Cobimetinib) for Use in Combination with Vemurafenib in Advanced BRAF V600 Mutation-Positive Melanoma

(Morningstar) Nov 25, 2015 - COTELLIC’s third regulatory approval, following Switzerland (August 2015) and the United States (November 2015).
read article »

Why Many Cancer Drugs Don't Have To Cost So Much

(Forbes) Nov 24, 2015 - Recently, a pharmacologist from England presented an eye-opening report on the price of cancer medications. The analysis – with a focus on costs of drug ingredients, manufacture and distribution – suggests that for some new cancer treatments, Americans are paying about 100 times more than what’s necessary.
read article »


View ALL News »

News Story Commentary By Academic and Community Oncologists

Express Scripts to Calculate 'Blended' Drug Prices (BioCentury)

The evaluation process by which ESI is going to establish the blended pricing is a new concept. While other value...posted by: Winston, Wong, PharmD

FDA Approves Portrazza To Treat Advanced Squamous Non-Small Cell Lung Cancer (FDA.gov)

Necitumumab is a treatment with significant side effects that improves survival by a median of less than two months....posted by: H. Jack West, MD

Doctors Call for Drug Advertising Ban in Position Reversal (Bloomberg)

As one who attended the HOD meeting the discussion on DTC advertising was lively. Both sides were heard. In...posted by: Thomas, Marsland, MD

Novartis Biosimilar Takes Aim At Amgen Drug Neulasta (Reuters)

Watching the impact of the Neupogen biosimilar and Granix is having on the market is interesting. Those who are...posted by: Winston, Wong, PharmD

Specialty Drugs Now Cost More Than the Median Household Income (Washington Post/Wonkblog)

This is an interesting way to put the high cost of specialty medications in perspective, and it is very effective....posted by: Winston, Wong, PharmD

OBR Training

Learn more about the OBR training platform, developed to provide an in-depth understanding of the unique business dynamics of today's oncology landscape.

OBR Job Board

Seattle Genetics has 1 job posted.

Check out the OBR Job Board here.

The most comprehensive and up-to-date oncology pipeline information on the web!
OBR Pipeline Online™

View company profiles, indexes, and streaming stock quotes of over 200 oncology focused companies.


Symbol  %Δ
KBIO +30.79%
CLVS +10.49%
TCON +9.85%
XBIT -8.03%
OHRP -7.13%
MNKD -5.02%


OBR Radar

View upcoming pivotal oncology events such as PDUFA dates, ODAC dates, and announcement of phase III clinical trial results

Date: December 19, 2015
Company: Merck
Product: Keytruda® (pembrolizumab)

Date: December 24, 2015
Company: Merck
Product: Keytruda® (pembrolizumab)

Date: December 2015
Company: XBiotech
Product: Xilonix™

See All OBR Radar items»